Averitas Pharma

Averitas Pharma is a pharmaceutical company committed to developing innovative alternatives for managing pain, with a strong focus on patient-centric solutions. The company seeks to address unmet patient needs through affordable access to treatments for neuropathic pain. Leveraging scientific research, including the discovery of the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor, Averitas Pharma aims to create a positive impact on patients' lives. With a legacy built on 75 years under the global healthcare company Grünenthal, Averitas Pharma is dedicated to approaching pain not just as a symptom, but as a disease that requires effective solutions.